



The Artificial Urinary Sphincter in Complex Situations

M. Fisch

Disclosures:


Overall

none with respect to this lecture (no financial affiliations within the last two years)

Member of the Scientific Board / grant of AMS / Boston Scientific in the past

Scientific Chair of meetings sponsored by Apogepha / Astellas

Artificial Urinary Sphincter



- Most predictable successful surgery in pts. with severe incontinence, after external beam radiation, after prior sling or AUS implantation
- It has the largest body of evidence reporting long-term success
- The success rates and high patient's satisfaction outweigh the need for revisions

LE 2, grade of recommendation B

Averbeck et al., Report from the 6th International Consultation on Incontinence, Neurourol Urodyn 2019

Systematic Review: pooled analysis

Outcome	Results % (range)
Infection / erosion	8.5 (3.3-27.8)
Mechanical failure	6.2 (2.0-13.8)
Urethral atrophy	7.9 (1.9-28.6)
Reintervention	26.0 (14.8-44.8)
Social continent (≤ 1 pad/24h)	79.0 (60.9-100)
Completely dry (0pad)	43.5 (4.3-85.7)

Van der Aa et al. Eur Urol 2013

Metaanalysis and

systematic review (after RPX)

dry rate	52 %
Social dry rate	82 %

Li et al, PLOS ONE 2023


27096 implants in the US 1972-2015

82.6% performed by **low volume implanters** (<5/year)

76.8% perineal approach

32.2% penoscrotal approach

8.2% tandem cuff



Postoperative Complications:

4% cuff erosion

3.8% fluid loss

2.4% subcuff atrophy

1.8% device infection

0.2% PRB herniation

21.1% explantation and /or revision

52.0% explantation only

37.7% revision only

10.2% explantation + revision

Device Survival: Kaplan –Meier explantation free device survival rates:

87.1%	5 years
78.3%	10 years

Penoscrotal approach / tandem cuff:

Higher rates of device infection, cuff erosion and fluid loss

Low volume surgeon:

Higher cuff erosion rates

Multivariate analysis:

Younger age, penoscrotal approach, tandem cuff associated with device explantation and revision but not surgeon volume



What are the results in complex situations?

- Influence of comorbidities
- St. p. irradiation
- St. P. urethroplasty
- Reimplantations
- Transcorporal cuff

Our Operative Technique


Incision

- perineal
- Suprainguinal
- penoscrotal approach






Positioning:

- balloon intraperitoneal
behind rectus muscle
- Pressure regulating
balloon 61-70
- Pump right scrotum




Filling: saline most commonly used

- Ultravist 150
 - Single cuff 22 cc
 - Double cuff 24 cc



Our Strategy: Cuff Location

- **Bladder neck**
 - neurogenic, females
- **Membranous urethra**
 - our favorite location
- **Bulbar urethra**
 - single cuff
 - option for redos after double cuff
 - distal double cuff
 - after radiation;
 - after reanatomosis (RPX)
 - transcorporal cuff
 - last option, salvage




Comorbidities: Single / Doublecuff

208 implantations, 4,5 year period, 11 pts lost to FU: 197 remaining

age: 70 (IQR9); ASA: 2 (IQR1); FU: 16.3 (IQR 24.25) m

Cuff Placement:

distal bulbar double cuff	64.2%
membraneous	30.1%
bladder neck	2.8%
transcorporal	2.8%



<u>Continence</u>	<u>objective</u>	<u>subjective</u>
double cuff	86.6%	90.2%
single cuff	69.1%	76.4%

Comorbidities: Single vs. Dcuff

Risk Factor Analysis:

Continence	p value	HR	lower CI	upper CI
single compared to double cuff	0.016	1.6	1.09	2.34
detrusor overactivity	0.001	2.64	1.65	4.25

Explantation

Age	0.012	1.1	1.02	1.19
ASA	0.496	1.35	0.572	3.167
diabetes mellitus	0.83	0.79	0.10	6.19
anticoagulant therapy	0.011	4.54	1.41	14.65
double cuff compared to single cuff	0.076	3.97	0.867	18.18

- ▶ DC significantly higher continence rates: **86.6% vs 69.1% (p=0.016)**
- ▶ tendency of higher complication rate for DC: **15.5% vs 8.3%**
- ▶ age, anticoagulant therapy risks factors for explantation


Since 2009 prospective database, 248 pts included, 2009 – 2015: n=155 distal double cuff, n=74 after irradiation, Follow-up: median 24 mo (IQR 7.25 - 36), no difference between the two collectives: age, ASA, comorbidities, median urine loss, prior surgeries

Complications	Overall	History of Rx	no Rx	p-value
Patients, n (%)	155 (100)	74 (47.7)	81 (52.3)	-
Infection (%)	7 (4.5)	5 (6.8)	2 (2.5)	0.260
Arrosion (%)	23 (14.8)	13 (17.6)	10 (12.3)	0.377
Explantation (%)	35 (22.6)	19 (25.7)	16 (19.8)	0.443
Mechanical Failure (%)	6 (3.9)	1 (1.4)	5 (6.2)	0.212

Continence	Overall	History of Rx	no Rx	p-value
Patients, n (%)	155 (100)	74 (47.7)	81 (52.3)	-
Objective continence (%)	120 (77.4)	57 (77)	63 (77.8)	0.691
Subjective continence (%)	127 (81.9)	63 (85.1)	64 (79)	0.666
Social continence(%)	134 (86.5)	66 (89.2)	68 (84)	0.804

Since 2009 prospective database, 248 pts included, 2009 – 2015: n=155 distal double cuff, n=74 after irradiation, Follow-up: median 24 mo (IQR 7.25 - 36), no difference between the two collectives: age, ASA, comorbidities, median urine loss, prior surgeries

Explantation rate: DC vs. DC st. p.. radiation



➤ No significant differences: continence, complications, explantation rates

Maurer et al, BJU Int 124:1040-1046, 2019

➤ No differences concerning outcome

Sathianathan et al. BJUI 2014; Jhavar et al. Clin Genitourin Cancer 2017

➤ Signif. higher revision rate after irradiation

Manunta et al. BJUI 2000; Brant et al. Urology 2014

➤ Signif. lower continence rate after irradiation

Guillaumier et al. Urol Ann 2017

Previous Urethroplasty

Since 2009 prospective database, 248 pts included, 2009 – 2015:
n=236, n=17 urethroplasty with buccal mucosa, Follow-up: median 24 mo (IQR 6 - 31)

	BMGU n=17 (100)	no BMGU n=219 (100)	p-value*
Patients, n (%)			-
Median age at surgery years (IQR)	70.0 (67.0-74)	70.0 (65.0-74.0)	0.82
Median urine loss			
Stress pad test, g (IQR)	119 (73-137.5)	108 (55.5-144)	0.357
Number of pads used/day (IQR)	7 (4.75-8.5)	7 (5-8)	0.803
Median ASA classification (IQR)	2 (2-3)	2 (2-3)	0.285
Comorbidities/previous surgeries, n (%)			
Diabetes mellitus	5 (29.4)	22 (10)	0.032
Anticoagulant therapy	6 (35.3)	83 (37.9)	0.526
Surgeries prior SUI, n (%)			
Radical prostatectomy	8 (47.1)	175 (79.9)	0.04
TUR-P	8 (47.1)	30 (13.7)	0.02
Trauma	1 (5.9)	5 (2.3)	0.365
Pelvic radiation therapy, n (%)	13 (76.5)	69 (31.5)	0.001
Surgeries prior AUS implantation, n (%)			
Open surgical therapy for SUI	4 (23.5)	65 (29.7)	0.401
Length of Buccalmucosagraft cm (IQR)	4 (3-5)	-	-
Median AUS operation time minutes (IQR)	62.5 (51-68)	58 (51-68)	0.307

Previous Urethroplasty

Since 2009 prospective database, 248 pts included,

2009 – 2015:

n=236, n=17 urethroplasty with buccal mucosa, Follow-up: median 24 mo (IQR 6 - 31)

Complications urethroplasty + AMS 800 vs. AMS 800

	BMGU	Comp Grp	p-value*
Patients, n (%)	n=17 (100.0)	n=219 (100)	-
Infection (%)	2 (11.8)	6 (2.7)	0.106
Arrosion (%)	2 (11.8)	23 (10.5)	0.559
Explantation (%)	4 (23.6)	36 (16.4)	0.320
Mechanical Failure (%)	0 (-)	8 (3.7)	0.545

Continence rates urethroplasty + AMS 800 vs. AMS 800

	BMGU	Comp Grp	p-value*
Patients, n (%)	n=17 (100.0)	n=219 (100)	-
Objective continence (%)	12 (70.6)	163 (75.8)	0.409
Subjective continence (%)	15 (88.2)	176 (81.5)	0.377
Social continence(%)	16 (94.1)	187 (87)	0.344

Previous Urethroplasty

Since 2009 prospective database, 248 pts included, 2009 – 2015:
n=236, n=17 urethroplasty with buccal mucosa, Follow-up: median 24 mo (IQR 6 - 31)

- **No significant differences: continence, complications, explantation rates**

Maurer et al, World J Urol 37: 647-653, 2019

- **Prospective multicenter study: urethroplasty is no significant risk factor
for higher complication rate**

Brant et al, J Urol 2014

- **Urthroplasty is a significant risk factor for a negative outcome
(complication and explantation rate)**

McGeady et al, J Urol 2014

Primary, Secondary & Repeat Implantation

Since 2009 prospective database, 248 pts included, 2009 – 2015: n=235, Median FU

n=165 (70.2%) primary implantation 24 (7-36) months

n= 46 (19.6%) secondary implantation 25.5 (7.75-36) months

(AUS after any other type of incontinence surgery)

n= 24 (10.2%) repeat implantation (AUS reimplantation) 14 (7-27) months

➤ **No significant differences in complication rates**

➤ **Three-year explantation free survival rates:**

82.3% primary

81.5% secondary

78.6% repeat

➤ **Signif. higher continence rates after secondary AUS implantation**

Primary, Secondary & Repeat Implantation

Since 2009 prospective database, 248 pts included, 2009 – 2015: n=235, Median FU

n=165 (70.2%) primary implantation

24 (7-36) months

n= 46 (19.6%) secondary implantation

25.5 (7.75-36) months

(AUS after any other type of incontinence surgery)

n= 24 (10.2%) repeat implantation (AUS reimplantation)

14 (7-27) months

Continence rates AMS 800

	Primary Aus (58.2% DC)	Repeat AUS (62.5%DC)	Secondary AUS (91.3% DC)	p-value prim vs sec.
Patients, n (%)	165 (100)	24 (100)	46 (100)	
Objective continence (%)	118 (71.5)	15 (62.5)	41 (89.1)	0.016
Subjective continence (%)	128 (77.6)	19 (79.2)	43 (93.5)	0.014
Social continence(%)	137 (83)	21 (87.5)	44 (95.7)	0.037

Transcorporal Cuff

Transcorporal Cuff with closure of corporal bodies

N= 39, median age 72 yrs, median Follow-up 27months

61.5% radiation




41% urethral surgery

96% after distal double cuff

Mean explantation free survival: 83 months

Continence:

- Objective 54.5%
- Subjective 69.7%
- Social 78.8%



- The artificial urinary sphincter remains the gold standard for treatment of male SUI
- DC has significant higher continence rate but tendency to higher complication rates
- Age and anticoagulant therapy are risk factors for explantation
- No significant differences concerning continence, complications and explantation rates in irradiated vs. nonirradiated patients in our series
- Comparable results concerning continence, complications and explantation rates in patients after urethroplasty with buccal mucosa in our series
- Comparable complication and explantation rates after primary, secondary and repeat implantation; secondary implantation: better continence rates in our series
- Transcorporal cuff: mean explant. free survival: 83 months,
Continence: objective 54.5%, subjective 69.7%



Thank You